Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

4 potential pulmonary fibrosis therapies to watch

By Brian Buntz | December 6, 2021

IPF

IPF image from Wikipedia

The drug development landscape in idiopathic pulmonary fibrosis is changing rapidly. “There are probably 30 or 40 different compounds in development,” said Dr. Toby Maher, a presenter at the Pulmonary Fibrosis Foundation (PFF) Summit held last month. Of those, a handful have reached Phase 2 and Phase 3 clinical trials. Here, we highlight a handful of pulmonary fibrosis therapy candidates.

1. Pamrevlumab

One of the pathways drug developers have explored to treat IPF involves connective tissue growth factor (CTGF). The protein signals to cells to stimulate the development of fibrotic tissue In IPF. “We know that there’s an excess of CTGF,” Maher said. “And we know that that can be blocked using antibodies.”

This observation led to the development of a monoclonal antibody first called FG3019 and later rechristened as pamrevlumab.

Developed by FibroGen (NSDQ:FGEN), Pamrevlumab is now the subject of two Phase 3 studies. One of those requires that participants not receive background treatment with the existing antifibrotic therapies, nintedanib or pirfenidone. In the second study, patients can receive background treatment with existing antifibrotic therapies.

2. Recombinant human pentraxin-2

Pentraxin is a protein in the blood with anti-inflammatory and antifibrotic properties. Individuals with pulmonary fibrosis may have a deficiency of pentraxin, which stirred interest in offering intravenous replacement pentraxin as a potential IPF treatment.

A Phase 3 trial followed a 2b open-label study that followed patients for 28 weeks. The Phase 2b trial tested the intravenous administration of the drug, which appeared to show a benefit in terms of forced vital capacity (FVC), which refers to the amount of exhaled air in the forced expiratory volume (FEV) test. “Importantly, the drug also appeared to have a beneficial effect on six-minute walk,” Maher said. “That’s a test where patients will walk up and down the corridor for six minutes, and we measure the distance they can walk in that time.” Participants taking pentraxin had stable six-minute walk distances, whereas those who received a placebo saw a reduction in walk distance over the same time.

The drug has since moved on to a Phase 3 study, which is now actively recruiting.

3. GB0139

Known initially as TD139, GB0139 inhibits galectin-3, a molecule found on the surface of inflammatory cells, including macrophages, which are inflammatory cells in the lung. “We know that these cells that express galectin-3 play a role in the development of fibrosis,” Maher said.

Having observed from preclinical models and animal studies that blocking galectin-3 has antifibrotic effects, Galecto (NSDQ:GLTO) is testing the potential of GB0139 as a potential treatment for idiopathic pulmonary fibrosis. “What’s particularly interesting about this drug is that it’s been developed in an inhaled form,” Maher said.

The drug has been studied in a small Phase 2a study. When delivered with an inhaler, the drug reached fibrotic regions of the lung and reduced local galectin-3 levels. The drug also appeared to lessen a biomarker known as platelet-derived growth factor.

A Phase 2b study focused on GB0139 is currently recruiting.

4. Treprostinil

Initially developed for the treatment of pulmonary hypertension, Treprostinil from United Therapeutics (NSDQ:UTHR) could also offer the potential to some patients with pulmonary fibrosis. Referring to high blood pressure in the blood vessels flowing through the lungs, pulmonary hypertension can occur alone and in individuals with chronic lung diseases such as pulmonary fibrosis.

Drug companies have tested a number of drugs in patients with pulmonary hypertension related to pulmonary fibrosis. “And unfortunately, almost all of those trials have been negative,” Maher said.

Treprostinil may potentially offer more promise for IPF patients with pulmonary hypertension.

The drug, which is a prostacyclin analog, dilates blood vessels in the lung. A trial of treprostinil involving patients with fibrotic interstitial lung disease found that treprostinil recipients had a noticeable improvement in their walk distance over the 16 weeks of the study. Conversely, placebo recipients had a slight deterioration in walk distance. The drug also appeared to have stabilized patients’ lung function over the trial. “This was a slightly unexpected apparent benefit of the drug,” Maher said.

Discontinued: Ziritixistat

Ziritixistat from Galapagos NV (NSDQ:GLPG) and Gilead Sciences (NSDQ:GILD) unfortunately won’t be a pulmonary fibrosis treatment — at least not for the foreseeable future. In February, the companies announced their decision to stop the ISABELA Phase 3 clinical trials exploring the autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. Galapagos also announced the discontinuation of the broader ziritaxestat research program in February 2021.

Even though the ISABELA studies were halted early, researchers are still interested in blocking autotaxin as a potential idiopathic pulmonary fibrosis treatment.

“There’s a lot of good data from basic science and cellular models to show that autotaxin plays a key role in the development and evolution of fibrosis,” Maher said. “And if we look in animal models, blocking autotaxin can help prevent fibrosis.”

One complication for the ISABELA trial was the difficulty in gauging the impact of the COVID-19 pandemic in the studies.


Filed Under: clinical trials, Drug Discovery, Pulmonology
Tagged With: GB0139, Pamrevlumab, pulmonary fibrosis, Recombinant human pentraxin-2, Treprostinil, Ziritixistat
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE